imvanex
bavarian nordic a/s - modificirana vakcina ankara - bavarska nordijska (mva-bn) virus - smallpox vaccine; monkeypox virus - drugih virusnih cjepiva, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 i 5. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
rispoval rs+pi3 intranasal
zoetis netherlands holdings b.v. podružnica zagreb za promidžbu, petra hektorovića 2, zagreb, hrvatska - Živi modificirani virus parainfluence goveda tip 3 (pi3v), soj rlb 103 ; Živi modificirani goveđi respiratorni sincicijski virus (brsv), soj 375 - liofilizat i otapalo za suspenziju za primjenu kroz nos - goveda (teladi)
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantel-stanica - antineoplastična sredstva - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
libmeldy
orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - ostali lijekovi protiv živčanog sustava - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.
rispoval 3 brsv+pi3+bvd
zoetis b.v., podružnica zagreb za promidžbu, petra hektorovića 2, zagreb, hrvatska - liofilizat:; Živi, modificirani virus parainfluence goveda tip 3 (pi3v), soj rlb 103 ; Živi, modificirani respiratorni sincicijski virus goveda (brsv), soj 375 ; otapalo:; inaktivirani virus virusnog proljeva goveda tip 1 (bvd, citopatogeni soj 5960 i necitopatogeni soj 6309) koji inducira seroneutralizirajući titar u zamorčadi - liofilizat i otapalo za suspenziju za injekciju - goveda (teladi)
akipor 6.3
arnika veterina d.o.o., vidikovac 20, 10000 zagreb, hrvatska - 1 doza (2 ml) cjepiva sadržava: liofilzat: živi, modificirani virus bolesti aujeszkog, ge, soj bartha ≥106.3 ccid50; diluent (uljni): tiomersal najviše 0,2 mg, uljni ekscipijent do 2,0 ml - liofilizat i uljni diluent za injekcijsku emulziju - imunološki vmp - svinja
plivak ks
genera d.d., svetonedeljska cesta 2, kalinovica, 10436 rakov potok, hrvatska - živi modificirani virus klasične svinjske kuge, kina soj - liofilizat za suspenziju - imunološki vmp - svinja
akipor 6.3
boehringer ingelheim animal health france scs, 29 avenue tony garnier, 69007 lyon, francuska - živi, modificirani virus bolesti aujeszkoga, ge- , soj bartha - liofilizat i uljni diluent za emulziju za injekciju - živi, modificirani virus bolesti aujeszkoga, ge- , soj bartha - svinja
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.